German drugmaker Merck KGaA has begun the second year of its five-year project to provide diabetes management courses for medical and pharmacy students in African Universities.
German drugmaker Merck KGaA has begun the second year of its five-year project to provide diabetes management courses for medical and pharmacy students in African Universities.
The Merck Capacity Advancement Program (CAP) will be provided at the Universities of Nairobi, Makerere, Uganda, and Namibia, before moving to Tanzania and Ghana. Merck is also offering every healthcare provider in those countries and the rest of Africa free access to the lectures via e-learning at www.managediabetesonline.org.
This year the company aims to reach 2,000 students and rural healthcare providers, who will have the opportunity to become “diabetes ambassadors” across Africa.
Merck’s Dr. Stefan Oschmann and Professor Sidat Mohsin, dean of the medical school at Eduardo Mondelane University, Mozambique.
The challenges faced by African countries in tackling diabetes are well known: services for the care of chronic diseases are poorly organized; public awareness about diabetes is limited, and well-structured education programs for patients and health professionals are unavailable.
According to the International Diabetes Federation, the number of people with diabetes in Africa could double by 2035. The proportion of deaths due to diabetes in people under 60 years in Africa is currently 76%, and 46% of people living with diabetes are still undiagnosed.
Next year Merck’s program will be extended to more universities across Africa such as Nigeria and Ethiopia, and to Asian countries such as Indonesia and India.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.